Finance

Lists
NVCT:NASDAQ
Nuvectis Pharma Inc
20,24 US$
+0,05%
(+0,010) 1D
20,24 US$
0,00% (0,00)
After hours
Closed: 13 ნოე, 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NVCT...
Open
20,17 US$
High
20,38 US$
Low
19,60 US$
Mkt. cap
696,03 მლნ.
Avg. vol.
196,39 ათ.
Volume
208,98 ათ.
52-wk high
29,28 US$
52-wk low
5,77 US$
EPS
-1,89 US$
Beta
-0,21
Shares outstanding
34,39 მლნ.
No. of employees
19
Open
20,17 US$
High
20,38 US$
Low
19,60 US$
Mkt. cap
696,03 მლნ.
Avg. vol.
196,39 ათ.
Volume
208,98 ათ.
52-wk high
29,28 US$
52-wk low
5,77 US$
EPS
-1,89 US$
Beta
-0,21
Shares outstanding
34,39 მლნ.
No. of employees
19
News stories
From web sources and news partners
RealMoney Pro
RealMoney Pro
·
45 წუთის წინ
Chips Slide Again, but the S&P 500 Still Ends the Week Up 2.5%
Traders Union
Traders Union
·
2 საათის წინ
S&P 500 gains $1.2 trillion in a week, Peter Tuchman notes
About Nuvectis Pharma Inc
CEO-
Employees19
Founded2020
HeadquartersFort Lee, ნიუ-ჯერსი, ამერიკის შეერთებული შტატები
SectorHealth Care
Industry-
Analyst ratings
Based on 3 analysts giving stock ratings to NVCT in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for NVCT in the last 3 months.
Highest
Current 20,24 US$
39,00 US$ (+92,69%)
Average
34,50 US$ (+70,45%)
Lowest
30,00 US$ (+48,22%)
Analyst
Recommendation
Action
Price target
Projected
Date
Naz Rahman
Maxim Group
Buy
Reiterated
30,00 US$
+48,2%
11/04/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
39,00 US$
+92,7%
11/04/2026
Pete Stavropoulos
Cantor Fitzgerald
Buy
Initiated
-
-
08/24/2026
Christopher Liu
Lucid Capital
Buy
Maintained
34,00 US$
+68%
08/05/2026
Jonathan Aschoff
Roth MKM
Buy
Reiterated
33,00 US$
+63%
07/06/2026
Unknown Analyst
Roth MKM
Buy
Maintained
20,00 US$
-1,2%
06/23/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5,09 მლნ.
4,11 მლნ.
4,68 მლნ.
27,37 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,53 მლნ.
2,15 მლნ.
2,51 მლნ.
3,68 მლნ.
Operating expense
7,62 მლნ.
6,26 მლნ.
7,20 მლნ.
31,05 მლნ.
Total operating expenses
7,62 მლნ.
6,26 მლნ.
7,20 მლნ.
31,05 მლნ.
Operating income
-7,62 მლნ.
-6,26 მლნ.
-7,20 მლნ.
-31,05 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
-7,31 მლნ.
-6,05 მლნ.
-7,02 მლნ.
-30,07 მლნ.
EBT excluding unusual items
-7,31 მლნ.
-6,05 მლნ.
-7,02 მლნ.
-30,07 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7,31 მლნ.
-6,05 მლნ.
-7,02 მლნ.
-30,07 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
303,00 ათ.
210,00 ათ.
177,00 ათ.
979,00 ათ.
Interest expense
-
-
-
-
Net interest expenses
303,00 ათ.
210,00 ათ.
177,00 ათ.
979,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google აპები